483
CMP Pharma IncFDA 483 - CMP Pharma Inc - December 21, 2016
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
CMP Pharma Inc, a drug manufacturer in Farmville, NC, received a Form 483 with two observations concerning its post-marketing adverse drug experience (ADE) reporting. The firm failed to report individual ADEs to the FDA in 15-day alerts and include them in periodic safety reports, and its written procedures for handling post-marketing ADEs were found to be inadequate. These deficiencies highlight significant issues in the firm's pharmacovigilance system.
Open in Dashboard
ID · e0d9c652-ef72-4a17-abbb-6e547f567f1d